These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33374546)

  • 21. Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis.
    Ozaki Y; Koide M; Furuya Y; Ninomiya T; Yasuda H; Nakamura M; Kobayashi Y; Takahashi N; Yoshinari N; Udagawa N
    PLoS One; 2017; 12(9):e0184904. PubMed ID: 28937990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts.
    Enjuanes A; Ruiz-Gaspà S; Peris P; Ozalla D; Alvarez L; Combalia A; Martínez de Osaba MJ; Monegal A; Pares A; Guañabens N
    Endocrine; 2010 Apr; 37(2):322-8. PubMed ID: 20960270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Icariin influences adipogenic differentiation of stem cells affected by osteoblast-osteoclast co-culture and clinical research adipogenic.
    Zhang S; Feng P; Mo G; Li D; Li Y; Mo L; Yang Z; Liang D
    Biomed Pharmacother; 2017 Apr; 88():436-442. PubMed ID: 28122309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
    Schubert A; Schulz H; Emons G; Gründker C
    Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased OPG/RANKL ratio in the conditioned medium of soybean-treated osteoblasts suppresses RANKL-induced osteoclast differentiation.
    Park K; Ju WC; Yeo JH; Kim JY; Seo HS; Uchida Y; Cho Y
    Int J Mol Med; 2014 Jan; 33(1):178-84. PubMed ID: 24248634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteoblasts play key roles in the mechanisms of action of strontium ranelate.
    Brennan TC; Rybchyn MS; Green W; Atwa S; Conigrave AD; Mason RS
    Br J Pharmacol; 2009 Aug; 157(7):1291-300. PubMed ID: 19563530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver X receptors orchestrate osteoblast/osteoclast crosstalk and counteract pathologic bone loss.
    Kleyer A; Scholtysek C; Bottesch E; Hillienhof U; Beyer C; Distler JH; Tuckermann JP; Schett G; Krönke G
    J Bone Miner Res; 2012 Dec; 27(12):2442-51. PubMed ID: 22806960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sanggenon C Stimulates Osteoblastic Proliferation and Differentiation, Inhibits Osteoclastic Resorption, and Ameliorates Prednisone-Induced Osteoporosis in Zebrafish Model.
    Wang H; Feng T; Guo D; Zhang M; Chen L; Zhou Y
    Molecules; 2018 Sep; 23(9):. PubMed ID: 30217005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
    Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
    Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression.
    Kim YH; Kim GS; Jeong-Hwa B
    Exp Mol Med; 2002 May; 34(2):145-51. PubMed ID: 12085990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Control of bone resorption by RANKL-RANK system].
    Harada S; Takahashi N
    Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
    Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
    J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of IL-1beta, PGE(2), and TGF-beta1 on the expression of OPG and RANKL in normal and osteoporotic primary human osteoblasts.
    Jurado S; Garcia-Giralt N; Díez-Pérez A; Esbrit P; Yoskovitz G; Agueda L; Urreizti R; Pérez-Edo L; Saló G; Mellibovsky L; Balcells S; Grinberg D; Nogués X
    J Cell Biochem; 2010 May; 110(2):304-10. PubMed ID: 20225238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis.
    Giner M; Rios MJ; Montoya MJ; Vázquez MA; Miranda C; Pérez-Cano R
    Eur J Pharmacol; 2011 Jan; 650(2-3):682-7. PubMed ID: 21050847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteoprotective effects of osthole in a mouse model of 5/6 nephrectomy through inhibiting osteoclast formation.
    Li X; Xue C; Wang L; Tang D; Huang J; Zhao Y; Chen Y; Zhao D; Shi Q; Wang Y; Shu B
    Mol Med Rep; 2016 Oct; 14(4):3769-76. PubMed ID: 27571745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.
    Trouvin AP; Goëb V
    Clin Interv Aging; 2010 Nov; 5():345-54. PubMed ID: 21228900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bisphosphonate inhibits bone turnover in OPG(-/-) mice via a depressive effect on both osteoclasts and osteoblasts.
    Shoji S; Tabuchi M; Miyazawa K; Yabumoto T; Tanaka M; Kadota M; Maeda H; Goto S
    Calcif Tissue Int; 2010 Aug; 87(2):181-92. PubMed ID: 20549197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
    Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
    Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.